HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-03-2014, 10:05 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide

Debra Hughes, MS
June 04, 2013 No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide as Adjuvant Treatment for Breast Cancer

CHICAGO―Single-agent paclitaxel did not show equivalence to doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer in women with zero to three axillary nodes, according to long-term results of the Cancer and Leukemia Group B (CALGB) 40101 study at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
This conclusion “is very unlikely to change with additional follow-up,” noted Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, Boston, MA, and colleagues on behalf of the CALGB. Paclitaxel was found to be less toxic than doxorubicin and cyclophosphamide.
The investigators enrolled patients with operable breast cancer with zero to three positive nodes. The study was designed to address the superiority of six versus four cycles of therapy as well as equivalence of single-agent paclitaxel to standard doxorubicin/cyclophosphamide.
“After enrolling 3,871 patients, the study closed in 2010 due to slowing accrual,” Dr. Shulman noted.
When the trial was activated in 2002, paclitaxel 80 mg/m2 was administered once weekly for 12 or 18 weeks and doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 was given every 3 weeks for four or six cycles. In 2003, with 570 patients enrolled, the schedules were revised to four or six cycles every 2 weeks for both paclitaxel 175 mg/m2 and doxorubicin/cyclophosphamide. The six-cycle arms were dropped in 2008, with 3,871 pts enrolled, because of slow accrual.
At a median follow-up of 6.1 years, there were 437 relapse-free survival (RFS) events. The hazard ratio (HR) of 1.26 (95% CI: 1.05-1.53; P=0.02) “did not allow a conclusion of equivalence of paclitaxel with doxorubicin/cyclophosphamide,” he said.
With 266 deaths, the HR for overall survival (OS) is 1.27 (95% CI: 1.00-1.62; P=0.05), favoring doxorubicin/cyclophosphamide. The estimated absolute advantage of doxorubicin/cyclophosphamide at 5 years is 3% (91% vs. 88%) for RFS and 1% (95% vs. 94%) for OS.
All nine treatment-related deaths occurred in patients who received doxorubicin/cyclophosphamide. Six of these patients had developed acute myeloid leukemia (AML) and one had developed myelodysplastic syndrome (MDS), all between 11 and 34 months after enrollment. The other two patients who died suffered from treatment-related cardiac toxicity.
'lizbeth is offline   Reply With Quote
Old 01-03-2014, 10:43 PM   #2
turtle
Member
 
Join Date: Mar 2012
Posts: 19
Re: No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide

That study is a little bit scary considering how many of us were treated with TCH- yikes!

But, can that 3% be mitigated thru exercise, vit D, diet etc- who knows!?!?!
turtle is offline   Reply With Quote
Old 01-03-2014, 10:52 PM   #3
turtle
Member
 
Join Date: Mar 2012
Posts: 19
Re: No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide

completely contradictory- and I'm glad- unless I'm misunderstanding-

http://her2support.org/vbulletin/sho...tch+treatments
turtle is offline   Reply With Quote
Old 01-04-2014, 10:01 AM   #4
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: No Equivalence for Paclitaxel vs Doxorubicin/Cyclophosphamide

I stumbled on this looking for the results of the 4 vs 6 question, and posted it as a reminder to myself to go back and read the study details.

Interesting conclusions. I think the title is a bit dramatic for the information. A 1% overall survival benefit, and 9 treatment deaths in the doxorubicin/cyclophosphamide arm.

I think adjuvant TCH was a good treatment choice for the time, and ACTH for its time. With pCR, I see the industry shifting toward TCHP which has the highest pCR, and a move to subtyping research.

What was not obvious was the data on the 4 vs 6 treatments. It was mentioned that the enrollment in the 6 treatment arm slowed in accrual and was dropped in 2008.

Are the numbers above based on 4 treatments? If so it looks quite similar to the 6 treatment numbers of DFS and OS.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 10:48 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter